https://mindmedicinelaw.com/briefing/blinding-challenges-in-psychedelic-trials-umbraa-s-role-in-the-us-and-eu-20261108-57366The Psychedelic Journalen2026-11-08T15:04:13.986552+00:00Blinding Challenges in Psychedelic Trials: UMBRAA’s Role in the US and EUpsychedelic clinical trials, blinding methodology, expectancy bias, UMBRAA, FDA guidance, active placebo, trial design, regulatory review, MDMA trials, psilocybin researchhttps://mindmedicinelaw.com/briefing/us-tightens-import-rules-for-foreign-psychedelic-suppliers-20261106-56800The Psychedelic Journalen2026-11-07T22:05:52.251442+00:00US Tightens Import Rules for Foreign Psychedelic Supplierscbp regulations, foreign importers, psychedelic research, customs brokers, controlled substances, clinical trial supply, us import compliance, supply chain risk, federal registerhttps://mindmedicinelaw.com/briefing/chemsex-prep-and-hiv-prevention-gaps-public-health-implications-20261106-57014The Psychedelic Journalen2026-11-07T22:05:40.761949+00:00Chemsex, PrEP, and HIV Prevention Gaps: Public Health Implicationschemsex, prep, hiv prevention, sexual health, structural barriers, public health policy, harm reduction, msm, integrated care, provider traininghttps://mindmedicinelaw.com/briefing/scoping-review-protocol-naturalistic-psychedelic-use-for-trauma-in-military-popu-20261106-56996The Psychedelic Journalen2026-11-07T22:05:29.261091+00:00Scoping Review Protocol: Naturalistic Psychedelic Use for Trauma in Military Populationsscoping review, psychedelics, military veterans, trauma, naturalistic settings, public health, safety, policy implications, mental health outcomeshttps://mindmedicinelaw.com/briefing/uk-scoping-review-clarifies-definitions-of-psychedelic-therapy-for-depression-20261106-57029The Psychedelic Journalen2026-11-07T22:05:18.333089+00:00UK Scoping Review Clarifies Definitions of Psychedelic Therapy for Depressionpsychedelic-assisted therapy, depression, united kingdom, clinical trials, conceptual frameworks, nhs, policy development, mental health, standardization, scoping reviewhttps://mindmedicinelaw.com/briefing/psilocybin-and-cocaine-addiction-clinical-research-and-policy-outlook-20261106-56945The Psychedelic Journalen2026-11-07T22:05:07.524762+00:00Psilocybin and Cocaine Addiction: Clinical Research and Policy Outlookpsilocybin, cocaine addiction, stimulant use disorder, clinical trials, regulatory policy, mechanism of action, psychedelic therapy, FDA, safety riskshttps://mindmedicinelaw.com/briefing/us-veterans-seek-ayahuasca-retreats-abroad-policy-and-access-gaps-20261106-56946The Psychedelic Journalen2026-11-07T22:04:55.548689+00:00US Veterans Seek Ayahuasca Retreats Abroad: Policy and Access Gapsayahuasca retreats, us veterans, psychedelic policy, mental health access, international regulation, first responders, ptsd treatment, safety risks, psychedelic therapy, policy reformhttps://mindmedicinelaw.com/briefing/exceptional-experiences-and-altered-states-implications-for-psychedelic-research-20261106-56995The Psychedelic Journalen2026-11-07T22:04:42.747126+00:00Exceptional Experiences and Altered States: Implications for Psychedelic Research Methodologyexceptional experiences, altered states of consciousness, psychedelic research, qualitative methods, phenomenology, clinical trial design, parapsychology, research ethics, FDA, non-local consciousnesshttps://mindmedicinelaw.com/briefing/ketamine-assisted-mindfulness-for-opioid-cravings-u-s-clinical-implications-20261106-57107The Psychedelic Journalen2026-11-07T22:04:31.315225+00:00Ketamine-Assisted Mindfulness for Opioid Cravings: U.S. Clinical Implicationsketamine-assisted therapy, mindfulness, opioid use disorder, body awareness, psychedelic-assisted treatment, clinical trials, regulatory policy, interoception, relapse prevention, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-alcohol-use-disorder-evidence-review-and-policy-implicati-20261106-56994The Psychedelic Journalen2026-11-07T15:05:51.951058+00:00Psilocybin Therapy for Alcohol Use Disorder: Evidence Review and Policy Implicationspsilocybin-assisted therapy, alcohol use disorder, systematic review, randomized controlled trials, functional unblinding, clinical trial design, regulatory policy, addiction treatment, psychedelic research, evidence certaintyhttps://mindmedicinelaw.com/briefing/pharmacist-guidance-on-psilocybin-clinical-integration-in-the-us-20261105-57000The Psychedelic Journalen2026-11-07T22:06:02.324175+00:00Pharmacist Guidance on Psilocybin: Clinical Integration in the USpsilocybin, pharmacist education, psychedelic-assisted psychotherapy, drug interactions, clinical integration, public health, mental health policy, regulatory landscape, patient safety, interdisciplinary carehttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-in-nucleus-accumbens-new-mechanistic-insights-20261105-57106The Psychedelic Journalen2026-11-07T15:06:04.917850+00:00Psilocybin’s Astrocytic Modulation in Nucleus Accumbens: New Mechanistic Insightspsilocybin, astrocytes, nucleus accumbens, gene regulation, psychedelic mechanisms, clinical trial design, glial cells, FDA policy, psychiatric disordershttps://mindmedicinelaw.com/briefing/brain-hierarchy-imaging-framework-advances-alzheimer-s-staging-20261104-56834The Psychedelic Journalen2026-11-08T15:05:01.331016+00:00Brain Hierarchy Imaging Framework Advances Alzheimer's Stagingalzheimer's disease, neuroimaging, brain hierarchy, network biomarkers, psychedelic research, clinical trials, amyloid, tau, functional mri, brain networkshttps://mindmedicinelaw.com/briefing/5-meo-dmt-clinical-pharmacology-review-implications-for-depression-trials-20261104-56868The Psychedelic Journalen2026-11-08T15:04:50.534424+00:005-MeO-DMT Clinical Pharmacology Review: Implications for Depression Trials5-meo-dmt, mebufotenin, treatment-resistant depression, clinical pharmacology, psychedelic trials, regulatory pathways, safety risks, synthetic vs natural, trial design, neuroplasticityhttps://mindmedicinelaw.com/briefing/immune-biomarkers-and-brain-changes-in-mdd-implications-for-psychedelic-trials-20261104-56878The Psychedelic Journalen2026-11-08T15:04:38.207859+00:00Immune Biomarkers and Brain Changes in MDD: Implications for Psychedelic Trialsimmune biomarkers, major depressive disorder, il-13, neuroplasticity, psychedelic trials, escitalopram, brain imaging, biomarker-driven research, astroglial activation, clinical trial designhttps://mindmedicinelaw.com/briefing/gasdermin-mediated-pyroptosis-in-depression-preclinical-insights-and-research-pr-20261104-56876The Psychedelic Journalen2026-11-08T15:04:26.996227+00:00Gasdermin-Mediated Pyroptosis in Depression: Preclinical Insights and Research Prioritiesgasdermin, pyroptosis, depression, neuroinflammation, gsdmd, gsdme, psychedelic research, preclinical evidence, mechanistic targets, neuroimmune modulationhttps://mindmedicinelaw.com/briefing/psychotria-nemorosa-alkaloids-preclinical-relief-for-fibromyalgia-in-mice-20261103-56873The Psychedelic Journalen2026-11-08T15:05:23.689948+00:00Psychotria nemorosa Alkaloids: Preclinical Relief for Fibromyalgia in Micepsychotria nemorosa, alkaloids, fibromyalgia, preclinical study, chronic pain, non-opioid therapies, animal models, pain management, drug discovery, psychedelic researchhttps://mindmedicinelaw.com/briefing/standardizing-outcomes-in-psychedelic-therapy-trials-for-life-limiting-illness-20261103-56871The Psychedelic Journalen2026-11-08T15:05:12.139888+00:00Standardizing Outcomes in Psychedelic Therapy Trials for Life-Limiting Illnesspsychedelic-assisted therapy, clinical trial outcomes, life-limiting illness, measurement instruments, standardization, core outcome sets, palliative care, regulatory science, quality of life, existential distresshttps://mindmedicinelaw.com/briefing/polydrug-use-and-ptsd-insights-from-mass-trauma-survivors-in-israel-20261103-56854The Psychedelic Journalen2026-11-07T15:06:46.253539+00:00Polydrug Use and PTSD: Insights from Mass Trauma Survivors in Israelpolydrug use, ptsd, mass trauma, psychedelics, recreational motives, self-medication, nova festival, public health, substance use patternshttps://mindmedicinelaw.com/briefing/bdnf-pathway-as-a-target-for-treatment-resistant-depression-mechanistic-insights-20261103-56880The Psychedelic Journalen2026-11-07T15:06:33.587941+00:00BDNF Pathway as a Target for Treatment-Resistant Depression: Mechanistic Insights and Clinical Implicationsbdnf, treatment-resistant depression, neuroplasticity, psychedelic research, precision psychiatry, epigenetics, clinical trial design, biomarkers, genetic polymorphismhttps://mindmedicinelaw.com/briefing/ketamine-s-anti-dyskinetic-effects-in-female-parkinson-s-models-preclinical-evid-20261103-56883The Psychedelic Journalen2026-11-07T15:06:18.493522+00:00Ketamine’s Anti-Dyskinetic Effects in Female Parkinson’s Models: Preclinical Evidence and Implicationsketamine, parkinson's disease, l-dopa-induced dyskinesia, sex differences, preclinical models, female rats, clinical trial design, regulatory policy, neuropharmacologyhttps://mindmedicinelaw.com/briefing/labram-eeg-foundation-model-implications-for-psychedelic-neuroscience-20261102-56845The Psychedelic Journalen2026-11-08T15:05:35.879649+00:00LaBraM EEG Foundation Model: Implications for Psychedelic Neuroscienceeeg foundation models, labramb, psychedelic neuroscience, biomarker discovery, clinical trial endpoints, machine learning in eeg, regulatory science, translational neuroscience, brain data analysishttps://mindmedicinelaw.com/briefing/systematic-review-no-effective-drugs-for-prolonged-grief-disorder-20261102-56842The Psychedelic Journalen2026-11-07T15:07:39.751085+00:00Systematic Review: No Effective Drugs for Prolonged Grief Disorderprolonged grief disorder, systematic review, pharmacological treatment, psychedelic-assisted therapy, clinical trials, mental health policy, bereavement, antidepressants, regulatory implicationshttps://mindmedicinelaw.com/briefing/ohio-state-launches-psilocybin-trial-for-depression-in-lung-cancer-patients-20261102-56943The Psychedelic Journalen2026-11-07T15:07:25.891657+00:00Ohio State Launches Psilocybin Trial for Depression in Lung Cancer Patientspsilocybin therapy, lung cancer depression, ohio state university trial, oncology psychedelics, clinical trial phase, palliative care innovation, fda regulation, mental health in cancer, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/music-therapy-and-psychedelics-in-psychiatric-care-review-and-implications-20261102-56844The Psychedelic Journalen2026-11-07T15:07:13.171947+00:00Music Therapy and Psychedelics in Psychiatric Care: Review and Implicationsmusic therapy, psychedelic treatment, psychiatric disorders, clinical trial design, depression, anxiety, ptsd, neural mechanisms, treatment protocolshttps://mindmedicinelaw.com/briefing/enantioselective-ketamine-analysis-in-pink-cocaine-forensic-and-policy-implicati-20261102-56888The Psychedelic Journalen2026-11-07T15:07:00.180605+00:00Enantioselective Ketamine Analysis in 'Pink Cocaine': Forensic and Policy Implicationsketamine enantiomers, pink cocaine, forensic drug analysis, capillary electrophoresis, high-performance liquid chromatography, drug diversion, chiral surveillance, public health monitoring, law enforcement, illicit drug markethttps://mindmedicinelaw.com/briefing/irb-oversight-in-us-psychedelic-research-positive-trends-and-persistent-gaps-20261101-57440The Psychedelic Journalen2026-11-08T22:04:38.036298+00:00IRB Oversight in US Psychedelic Research: Positive Trends and Persistent Gapsirb oversight, psychedelic research, us clinical trials, research ethics, participant safety, regulatory policy, knowledge gaps, protocol approval, investigator experiencehttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-depression-early-trial-insights-2026-20261101-57443The Psychedelic Journalen2026-11-08T22:04:26.430737+00:00MDMA-Assisted Therapy for Depression: Early Trial Insights (2026)mdma-assisted therapy, major depressive disorder, alexithymia, self-compassion, wellbeing, clinical trial design, psychedelic research, fda guidance, mental health endpointshttps://mindmedicinelaw.com/briefing/ocd-comorbidity-and-biomarkers-implications-for-psychedelic-research-20261101-56847The Psychedelic Journalen2026-11-08T15:05:49.560361+00:00OCD Comorbidity and Biomarkers: Implications for Psychedelic Researchocd comorbidity, psychedelic research, biomarkers, serotonergic system, glutamatergic targets, clinical trial design, neuromodulation, circuit-level mechanisms, regulatory guidancehttps://mindmedicinelaw.com/briefing/ketamine-s-cell-type-specific-modulation-of-serotonergic-neurons-mechanistic-ins-20261101-57054The Psychedelic Journalen2026-11-07T22:04:19.139118+00:00Ketamine’s Cell-Type-Specific Modulation of Serotonergic Neurons: Mechanistic Insights for Antidepressant Researchketamine, serotonergic neurons, dorsal raphe nucleus, trkB pathway, rapid antidepressants, cell-type specificity, biomarkers, clinical trial design, psychedelic research, mechanistic insightshttps://mindmedicinelaw.com/briefing/ketamine-bladder-toxicity-clinical-and-policy-implications-global-2026-20261101-56899The Psychedelic Journalen2026-11-07T15:07:54.278016+00:00Ketamine Bladder Toxicity: Clinical and Policy Implications (Global, 2026)ketamine bladder toxicity, urinary tract complications, psychedelic therapy safety, bladder dysfunction, clinical protocols, regulatory policy, risk mitigation, psychiatric indications, adverse events monitoring